TY - JOUR
T1 - Therapy innovations
T2 - Tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors
AU - Raymond, Eric
AU - Hobday, Timothy
AU - Castellano, Daniel
AU - Reidy-Lagunes, Diane
AU - García-Carbonero, Rocío
AU - Carrato, Alfredo
N1 - Funding Information:
Acknowledgments The author acknowledges Dr. Ximena Alvira from HealthCo SL (Madrid, Spain) for her assistance in the preparation of this manuscript and Pfizer Spain for the financial support of medical writing services.
PY - 2011/3
Y1 - 2011/3
N2 - Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show limited sensitivity to cytotoxic agents, requiring the search for novel therapies. Recently, data from a phase III trial demonstrated that sunitinib produces a clinically significant improvement in progression-free survival in patients with unresectable, advanced, or metastatic GEP-NETs. Based on this finding, sunitinib became the first targeted drug approved for the treatment of GEP-NETs, paving the way for the approval of other anticancer agents in this drug-orphan disease. To date, results of trials involving other multitargeted tyrosine kinase inhibitors, such as sorafenib, the monoclonal antibody bevacizumab, and insulin-like growth factor 1 receptor inhibitors, have also shown promising results, and some are already being studied in phase III trials. This review updates the results of ongoing trials using inhibitors of growth factors and tyrosine kinase receptors involved in the carcinogenesis of GEP-NETs.
AB - Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) show limited sensitivity to cytotoxic agents, requiring the search for novel therapies. Recently, data from a phase III trial demonstrated that sunitinib produces a clinically significant improvement in progression-free survival in patients with unresectable, advanced, or metastatic GEP-NETs. Based on this finding, sunitinib became the first targeted drug approved for the treatment of GEP-NETs, paving the way for the approval of other anticancer agents in this drug-orphan disease. To date, results of trials involving other multitargeted tyrosine kinase inhibitors, such as sorafenib, the monoclonal antibody bevacizumab, and insulin-like growth factor 1 receptor inhibitors, have also shown promising results, and some are already being studied in phase III trials. This review updates the results of ongoing trials using inhibitors of growth factors and tyrosine kinase receptors involved in the carcinogenesis of GEP-NETs.
KW - Angiogenesis
KW - Bevacizumab
KW - Carcinoid tumors
KW - IGF-1R
KW - Orphan disease
KW - Pancreatic neuroendocrine tumors
KW - Sorafenib
KW - Sunitinib
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=79953308250&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953308250&partnerID=8YFLogxK
U2 - 10.1007/s10555-011-9291-2
DO - 10.1007/s10555-011-9291-2
M3 - Article
C2 - 21308478
AN - SCOPUS:79953308250
SN - 0167-7659
VL - 30
SP - S19-S26
JO - Cancer and Metastasis Reviews
JF - Cancer and Metastasis Reviews
IS - SUPPL. 1
ER -